TY - JOUR
T1 - Charged nanoparticles as protein delivery systems
T2 - A feasibility study using lysozyme as model protein
AU - Cai, Cuifang
AU - Bakowsky, Udo
AU - Rytting, Erik
AU - Schaper, Andreas K.
AU - Kissel, Thomas
N1 - Funding Information:
Cuifang Cai would like to acknowledge the German Academic Exchange Service (Deutsche Akademische Austauschdienst, DAAD) for the financial support. We thank Johannes Sitterberg for the AFM images, and Michael Hellwig for his assistance about TEM and SEM images.
Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2008/5
Y1 - 2008/5
N2 - The aim of this study was to investigate the feasibility of negatively charged nano-carriers (nanoparticles), consisting of polymer blends of poly(lactide-co-glycolide) (PLGA) and poly(styrene-co-4-styrene-sulfonate) (PSS), to improve the loading capacity and release properties of a positively charged model protein, lysozyme, through an adsorption process. Nanoparticles were prepared by a solvent displacement method and characterized in terms of size, ζ-potential, morphology, as well as loading capacity of model protein lysozyme. Morphology of these particles was investigated using transmission electron microscopy (TEM), scanning electron microscopy (SEM) and atomic force microscopy (AFM). The loading capacity of lysozyme was evaluated as a function of polymer blend ratio, protein concentration, pH, and ionic strength; in vitro release profiles were also studied. The results show that negatively charged nanoparticles were obtained using polymer blends of PLGA and PSS, characterized by increased net negative surface charge with increasing ratios of PSS. Moreover, protein loading capacity increased as function of PSS/PLGA ratio. Increased pH facilitated the adsorption process and improved the loading capacity. Maximum loading efficiency was achieved at salt concentrations of 50 mM. In vitro release of lysozyme from the polymer blend nanoparticles was dependent on drug loading and full bioactivity of lysozyme was preserved throughout the process. These findings suggest that this is a feasible method to prepare nanoparticles with high surface charge density to efficiently adsorb oppositely charged protein through electrostatic interactions.
AB - The aim of this study was to investigate the feasibility of negatively charged nano-carriers (nanoparticles), consisting of polymer blends of poly(lactide-co-glycolide) (PLGA) and poly(styrene-co-4-styrene-sulfonate) (PSS), to improve the loading capacity and release properties of a positively charged model protein, lysozyme, through an adsorption process. Nanoparticles were prepared by a solvent displacement method and characterized in terms of size, ζ-potential, morphology, as well as loading capacity of model protein lysozyme. Morphology of these particles was investigated using transmission electron microscopy (TEM), scanning electron microscopy (SEM) and atomic force microscopy (AFM). The loading capacity of lysozyme was evaluated as a function of polymer blend ratio, protein concentration, pH, and ionic strength; in vitro release profiles were also studied. The results show that negatively charged nanoparticles were obtained using polymer blends of PLGA and PSS, characterized by increased net negative surface charge with increasing ratios of PSS. Moreover, protein loading capacity increased as function of PSS/PLGA ratio. Increased pH facilitated the adsorption process and improved the loading capacity. Maximum loading efficiency was achieved at salt concentrations of 50 mM. In vitro release of lysozyme from the polymer blend nanoparticles was dependent on drug loading and full bioactivity of lysozyme was preserved throughout the process. These findings suggest that this is a feasible method to prepare nanoparticles with high surface charge density to efficiently adsorb oppositely charged protein through electrostatic interactions.
KW - Charge density
KW - Charged nanoparticles
KW - Electrostatic interaction
KW - Lysozyme
KW - Protein delivery
UR - http://www.scopus.com/inward/record.url?scp=41549119777&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=41549119777&partnerID=8YFLogxK
U2 - 10.1016/j.ejpb.2007.10.005
DO - 10.1016/j.ejpb.2007.10.005
M3 - Article
C2 - 18023160
AN - SCOPUS:41549119777
SN - 0939-6411
VL - 69
SP - 31
EP - 42
JO - European Journal of Pharmaceutics and Biopharmaceutics
JF - European Journal of Pharmaceutics and Biopharmaceutics
IS - 1
ER -